Event Details

Data on Immatics' PRAME cell therapy, IMA203, were presented at the 2025 ASCO® Annual Meeting in Chicago.

For more information, read the press release here and watch the oral presentation recording here.
 

+++
 

Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma

Presenting author: Martin Wermke, MD

Abstract Link: Program Guide – ASCO Meeting Program Guide - Oral Presentation

Video Recording: ASCO Oral Presentation IMA203 PRAME Cell Therapy – Recording

Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma

Presenting author: Jason Luke, MD, FACP, FASCO

Abstract Link: Program Guide – ASCO Meeting Program Guide - Trial-in-Progress Poster